Concerto Biosciences

Concerto Biosciences has dosed the first participant in a Phase 1 trial of ENS-002, our live biotherapeutic targeting S. aureus virulence to treat atopic dermatitis (eczema). Harnessing a trio of microbes discovered by mapping the network of microbial interactions on the skin, ENS-002 addresses a root microbial deficiency underlying atopic dermatitis in its quest to offer relief with fewer side effects. A milestone for microbial medicine, the commencement of this clinical trial offers a glimpse of what’s possible when we rethink complex disease through the lens of ecology.

Next week at the International Conference for Microbiome Engineering (ICME), Chief Scientific Officer Jared Kehe will showcase Concerto’s approach to mapping the vast interaction network of skin microbes, using eczema as a case study. Discover how our kChip platform enables us to systematically decode complex microbial relationships, with record-breaking speed, powering new solutions for skin health and beyond. Hope to see you there!

We had a great 2 days at the Partnerships in Drug Delivery #PODD Conference in Boston with team members Professor Andrew Lewis and Dr Lara Zibners representing Calla Lily.? ?Besides Andy’s well received presentation on our #Callavid vaginal drug delivery platform, there were also superb connections made with the wider #drugdelivery technology community, and exciting follow-ups to pursue.? The trip included a great catch-up with the groundbreaking #microbiome company Concerto Biosciences led by Cheri Ackerman.?Already looking forward to #PODD2025 next year! #womenshealth #healthcareinnovation #femtech #bthechange #miscarriagesupport #vaginalmicrobiome PODD: Partnership Opportunities in Drug Delivery Community News #PODD2024 #ivfsupport #endometriosis #bvtreatment #callavid #drugdelivery

Each quarter, as the seasons change, all the Concertians gather at HQ to bring renewed energy and focus?to our work. Against the backdrop of brilliant autumn leaves in Cambridge, our on-site was filled with the same crisp, radiant spirit—ideas sparking, connections deepening, our shared purpose glowing bright. Here’s to the Concertians this fall. ??

The countdown is on! A reminder that the final early bird prices for?Microbiome Connect?end tomorrow - October 18 ? With?Pfizer, Unilever, FDA, Concerto Biosciences?and?Vedanta Biosciences, Inc. confirmed, secure your spot?to join them at the only global meeting for the microbiome therapeutic & scientific community to retrieve R&D and commercial market intelligence. Why wait to pay the full rate??Book before midnight tomorrow and save $400: https://lnkd.in/eCWtgESx

Concerto is a huge proponent of founder-led biotech—and an example of it: We started out as academics-turned-cofounders, dreaming of turning our academic prototype into a product discovery engine.?Four years later, our first product is entering clinical trials. Two of the cofounders—CEO Cheri Ackerman and CSO Jared Kehe—are thrilled to once again participate as co-hosts of the 2024 Founder-Led Biotech Tour during its Boston stop (Nov 20). We hope to see you there. Registration link: https://founderledbio.com Major thanks to Pillar VC and Tony Kulesa for championing this movement and organizing this tour.

Meet the Start-Up Focused on Microbe-Tech: Concerto Biosciences. ?? From eczema to agriculture, Concerto Biosciences uses microbes to rewrite the playbook on health and sustainability. Discover how their kChip technology could make microbes the key to advanced biotech solutions in this episode of the Tech Optimist Podcast: https://lnkd.in/ej4gQ4jp.

Concerto's clinical trial, ENS-002 for Atopic Dermatitis in Adults, is now recruiting. The study site is in Austin, TX. If you are interested in learning more about it, you can connect with the research site here: https://lnkd.in/e_v7hY2C.

Eczema goes deeper than the skin—it impacts every part of life. The constant itch, sleepless nights, and harsh treatments weigh on millions of people. Introducing ENS-002, a groundbreaking microbial therapy from Concerto Biosciences. It leverages the skin’s natural bacteria to disarm S. aureus—a major trigger for eczema flares—without the risks of steroids or immunosuppressants. Watch our latest ENS-002 video featuring SAB members Peter Lio, MD, Tiffany Scharschmidt, MD, and Paul Blainey, PhD to learn how we’re transforming eczema care and advancing skin health.

??? We are excited to introduce the nine companies selected for our inaugural 2024 Healthcare and Technology Accelerator Program! These women are driving transformational solutions in key areas such as cancer diagnostics, antimicrobial resistance, and at-home diagnostics - each working to improve patient care and outcomes. Throughout this accelerator program, these companies will participate in a dynamic series of workshops, led by industry experts, and gain access to Springboard’s vast network of advisors to accelerate their growth and impact. Read more here: https://lnkd.in/gwx9xjBX Meet the 2024 Cohort: ? Phuong Jean Pham, Cellens Inc: Non-invasive cancer diagnostics powered by mechanobiology and machine learning. ? Cheri Ackerman, Concerto Biosciences: Unlocking microbial ecosystem insights for groundbreaking healthcare solutions. ? Julie B. Kennedy, RubyWell: Supporting family caregivers with financial stability through an intelligent, automated platform. ? Amanda (Curtis) Burkardt, PHIOGEN: Next-gen antibiotics tackling antimicrobial resistance. ? Pahini Pandya, Panakeia: AI-driven molecular biomarker analysis from H&E tissue images. ? Martha Sklavos PhD, PMP, PhD, Aloe Therapeutics: Enhancing immunotherapy for hard-to-treat solid tumors. ? Amy Urban DMD, DMD, Urban Innovations: Improving sleep quality with non-pharmacological solutions. ? Nathalya Mamane, RT MicroDx: Saliva-based at-home diagnostics for bacterial and viral pathogens. ? Adrianna Cantu, Revealix: Preventing diabetic foot complications through mobile thermography.